Genfit S.A. (EPA:GNFT)
France · Delayed Price · Currency is EUR 8.80
-0.09 (-1.01%)
Oct 23, 2026, 9:15 AM CEST
Genfit Earnings Call Transcripts
Fiscal Year 2026
-
The event highlighted the urgent need for scalable, accurate MASH diagnostics as new therapies shift the market focus to patient identification and monitoring. NIS2+ is validated as a superior, non-invasive test, with strong clinical and commercial prospects, supported by pharma partnerships and a robust roadmap to global adoption.